Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels

Neoplasia

Volumn 13, Issue 2, 2011, Pages 108-119

  Tang, Yaxiong ^a   Parmakhtiar, Basmina ^b   Simoneau, Anne R ^a   Xie, Jun ^a   Fruehauf, John ^b   Lilly, Michael ^b   Zi, Xiaolin ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; LYCOPENE; LYCOVIT; PHOSPHOTRANSFERASE INHIBITOR; PICROPODOPHYLLIN; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CASTRATION; CELL STRAIN LNCAP; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 79951471546     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101092     Document Type: Article

References (49)

1. Hsing AW and Devesa SS (2001). Trends and patterns of prostate cancer: whatdo they suggest? Epidemiol Rev 23, 3-13.
2. Feldman BJ and Feldman D (2001). The development of and rogen-independentprostate cancer. Nat Rev Cancer 1, 34-45.
3. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, and Pazdur R (2004). Approval summary: docetaxel in combination with prednisone for the treatmentof and rogen-independent hormone-refractory prostate cancer. Clin Cancer Res 10, 8147-8151.
4. Haenszel W and Kurihara M (1968). Studies of Japanese migrants. I. Mortalityfrom cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40, 43-68.
5. Crawford ED (2003). Epidemiology of prostate cancer. Urology 62(6 suppl 1), 3-12.
6. Culig Z (2004). Androgen receptor cross-talk with cell signaling pathways. Growth Factors 22, 179-184.
7. Clinton SK (1998). Lycopene: chemistry, biology, and implications for humanhealth and disease. Nutr Rev 56(2 pt 1), 35-51.
8. Campbell JK, Engelmann NJ, Lila MA, and Erdman JW (2007). Phytoene, phytofluene, and lycopene from tomato powder differentially accumulate in tissuesof male Fisher 344 rats. Nutr Res 27, 794-801.
9. Wertz K, Siler U, and Goralczyk R (2004). Lycopene: modes of action to promoteprostate health. Arch Biochem Biophys 430, 127-134.
10. Erdman JW Jr, Ford NA, and Lindshield BL (2009). Are the health attributesof lycopene related to its antioxidant function? Arch Biochem Biophys 483, 229-235.
11. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, and Willett WC (1995). Intake of carotenoids and retinol in relation to risk of prostatecancer. J Natl Cancer Inst 87, 1767-1776.
12. Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, and Wertz K (2004). Lycopene and vitamin E interfere with autocrine/paracrine loops inthe Dunning prostate cancer model. FASEB J 18, 1019-1021.
13. Liu X, Allen JD, Arnold JT, and Blackman MR (2008). Lycopene inhibits IGF-Isignal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis 29, 816-823.
14. Liu C, Lian F, Smith DE, Russell RM, and Wang XD (2003). Lycopene supplementationinhibits lung squamous metaplasia and induces apoptosis via up-regulatinginsulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 63, 3138-3144.
15. van Breemen RB and Pajkovic N (2008). Multitargeted therapy of cancer bylycopene. Cancer Lett 269, 339-351.
16. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, and Cui X (2008). The type Iinsulin-like growth factor receptor pathway: a key player in cancer therapeuticresistance. Front Biosci 13, 3273-3287.
17. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, and Cox ME (2004). Increased insulin-like growth factor I receptor expressionand signaling are components of and rogen-independent progression in alineage-derived prostate cancer progression model. Cancer Res 64, 8620-8629.
18. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, and Wu JD (2007). An antibody targeting the type I insulin-likegrowth factor receptor enhances the castration-induced response in and rogendependentprostate cancer. Clin Cancer Res 13, 6429-6439.
19. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, et al. (2006). Interleukin 6, a nuclearfactor-κB target, predicts resistance to docetaxel in hormone-independent prostatecancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumoractivity. Clin Cancer Res 12, 5578-5586.
20. Feng S, Tang Q, Sun M, Chun JY, Evans CP, and Gao AC (2009). Interleukin-6increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8, 665-671.
21. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, and Blumberg JB (2008). Should supplemental antioxidant administration be avoided during chemotherapyand radiation therapy? J Natl Cancer Inst 100, 773-783.
22. Rehman A, Bourne LC, Halliwell B, and Rice-Evans CA (1999). Tomato consumptionmodulates oxidative DNA damage in humans. Biochem Biophys Res Commun 262, 828-831.
23. Porrini M and Riso P (2000). Lymphocyte lycopene concentration and DNAprotection from oxidative damage is increased in women after a short period of tomato consumption. J Nutr 130, 189-192.
24. Hsiao G, Wang Y, Tzu NH, Fong TH, Shen MY, Lin KH, Chou DS, and Sheu JR (2005). Inhibitory effects of lycopene on in vitro platelet activation and in vivoprevention of thrombus formation. J Lab Clin Med 146(4), 216-226.
25. Lu Y, Zi X, Zhao Y, Mascarenhas D, and Pollak M (2001). Insulin-like growthfactor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93, 1852-1857.
26. Zi X and Simoneau AR (2005). Flavokawain A, a novel chalcone from kavaextract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumorgrowth in mice. Cancer Res 65, 3479-3486.
27. Sobel RE and Sadar MD (2005). Cell lines used in prostate cancer research: acompendium of old and new lines-part 1. J Urol 173, 342-359.
28. Zimmerman RA and Thompson IM Jr (2002). Prevalence of complementarymedicine in urologic practice. A review of recent studies with emphasis on useamong prostate cancer patients. Urol Clin North Am 29, 1-9.
29. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, Grignon D, Bertram JS, et al. (2001). Phase II randomized clinical trial of lycopenesupplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10, 861-868.
30. Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino RJr, Lovato J, Harmon M, et al. (2006). Phase I-II prospective dose-escalating trialof lycopene in patients with biochemical relapse of prostate cancer after definitivelocal therapy. Urology 67, 1257-1261.
31. Ansari MS and Gupta NP (2003). A comparison of lycopene and orchidectomyvs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92, 375-378.
32. Schwenke C, Ubrig B, Thürmann P, Eggersmann C, and Roth S (2009). Lycopenefor advanced hormone refractory prostate cancer: a prospective, open phase II pilotstudy. J Urol 181, 1098-1103.
33. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, and Wilding G (2008). Jun D mediates and rogen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate 68, 924-934.
34. Venkateswaran V, Fleshner NE, Sugar LM, and Klotz LH (2004). Antioxidantsblock prostate cancer in Lady transgenic mice. Cancer Res 64, 5891-5896.
35. Venkateswaran V, Klotz LH, Ramani M, Sugar LM, Jacob LE, Nam RK, and Fleshner NE (2009). A combination of micronutrients is beneficial in reducingthe incidence of prostate cancer and increasing survival in the Lady transgenicmodel. Cancer Prev Res (Phila) 2, 473-483.
36. Limpens J, Schröder FH, de Ridder CM, Bolder CA, Wildhagen MF, Obermüller-Jevic UC, Krämer K, and van Weerden WM (2006). Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancercells in nude mice. J Nutr 136, 1287-1293.
37. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltrán L, Moats S, Ramirez A, Jorcano J, and Conti C (2000). Deregulated expression of insulinlikegrowth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97, 3455-3460.
38. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, and Macaulay VM (2002). Expression of the type 1 insulin-like growth factor receptor is upregulatedin primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62, 2942-2950.
39. Genua M, Pandini G, Sisci D, Castoria G, Maggiolini M, Vigneri R, and Belfiore A (2009). Role of cyclic AMP response element-binding protein in insulin-likegrowth factor-I receptor up-regulation by sex steroids in prostate cancer cells. Cancer Res 69, 7270-7277.
40. Riso P, Brusamolino A, Martinetti A, and Porrini M (2006). Effect of a tomatodrink intervention on insulin-like growth factor (IGF)-1 serum levels in healthysubjects. Nutr Cancer 55, 157-162.
41. Graydon R, Gilchrist SE, Young IS, Obermüller-Jevic U, Hasselwander O, and Woodside JV (2007). Effect of lycopene supplementation on insulin-like growthfactor-1 and insulin-like growth factor binding protein-3: a double-blind, placebocontrolledtrial. Eur J Clin Nutr 61, 1196-1200.
42. Liu A, Pajkovic N, Pang Y, Zhu D, Calamini B, Mesecar AL, and van Breemen RB (2006). Absorption and subcellular localization of lycopene in human prostatecancer cells. Mol Cancer Ther 5, 2879-2885.
43. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, et al. (2007). Potential applications for circulatingtumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13, 3611-3616.
44. Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, Ulivi P, Rosetti M, Vannini I, Arienti C, Zoli W, et al. (2008). Mitotic catastrophe and apoptosis induced bydocetaxel in hormone-refractory prostate cancer cells. J Cell Physiol 217, 494-501.
45. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, et al. (2009). Docetaxel-induced prostatecancer cell death involves concomitant activation of caspase and lysosomalpathways and is attenuated by LEDGF/p75. Mol Cancer 8, 68.
46. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, and Kroemer G (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23(16), 2825-2837.
47. Zhang M, Latham D, Delaney M, and Chakravarti A (2005). Survivin mediatesresistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474-2482.
48. Vaira V, Lee C, Goel H, Bosari S, Languino L, and Altieri D (2007). Regulationof survivin expression by IGF-1/mTOR signaling. Oncogene 26, 2678-2684.
49. Shariat S, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, and Ashfaq R (2005). Survivin expression is associated with features of biologicallyaggressive prostate carcinoma. Cancer 100, 751-757.